Goat anti Human OCIL antibody
recognizes c-type lectin domain family 2 member D, also known as CLC2D, CLAX, and LLT1.
Originally described as an osteoblast-derived inhibitory factor of osteoclasts (Zhou et al.. 2001
), OCIL is a member of the C-type lectin-like receptor superfamily (CTLR). OCIL is expressed on lymphocytes including B cells, NK cells, T cells, and activated dendritic cells. At the cell surface, OCIL acts as a ligand for the NKRP1A receptor (CD161), which contributes to differentiation of lymphocytes (Marrufo et al.. 2018
). Interaction between OCIL and CD161 appears to actively participate in the anti-tumoral immune response, and have both been suggested as targets for immunotherapy strategies to enhance immune responses (Braud et al.. 2018
). The suggestion of OCIL as a target for immunotherapy has been strengthened by the finding that it is expressed in a variety of healthy tissues and in immune-privileged sites (Llibre et al.. 2016
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of Ocil antibody
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Western Blotting
- Goat anti Human OCIL antibody detects a band of approximately 30 to 35 kDa in cell lysates.